For far too long there has been a gap between payers and diagnostic companies where diagnostic technology has been characterized as “expensive and unnecessary”, because it has been poorly understood, undervalued and underutilized. Alva10 was established in response to this divide. With years of experience in pharmaceutical and diagnostic companies, Founders Hannah Mamuszka and Lena Chaihorsky built a team and company dedicated to narrowing that knowledge gap. Armed with and driven by knowledge, curiosity and a passion to innovate the industry, Alva10 set out to redesign the healthcare system while restructuring current spiraling healthcare spend. Read more about how Alva10 was founded here.
Alva10 reduces ineffective therapeutic spend through customized solutions that provide advanced knowledge of patients’ ability to respond to costly therapies before they are given. Through our proprietary model M.A.T.E. we restructure the relationship between health insurance payers and Precision Medicine diagnostic companies. The result of this new way of doing business is a broad range of completely novel healthcare tools that directly solve the large clinical and economic challenges for payers and providers.
In partnering with us, we enable our payer and provider partners to source innovations for their greatest needs. Our industry-leading asset of Precision Medicine technology curation ensures that those partners receive the best-in-class tool for their particular problem.
In the USA, our healthcare system readily pays for drugs and procedures, but not for the diagnostics that can tell us whether those will work for the individual patient. The concept of ‘Precision Medicine’—using diagnostic tools, combined with other patient health information to make informed, patient-specific decisions about treatment—requires that diagnostics be available in the market, used by physicians, and reimbursed by payers in order to impact and improve patient care.
ABOUT ALVA10
Founding Team
Hannah Mamuszka is Founder and Chief Executive Officer at Alva10, which she founded in 2015 to spur change in healthcare to allow more patients better access to diagnostic technology. Hannah’s career has spanned the laboratory and business sides of healthcare in both the pharma and diagnostics industries. Prior to Alva10, Hannah was VP of Exosome Diagnostics (acquired by BioTechne), where she led some of the earliest deals in the liquid biopsy space. Earlier in her career, she was Global Director of Pharmaceuticals Services for Oncotech, and then by acquisition, Exiqon (acquired by QIAGEN), where she built the Pharmaceutical Services and Companion Diagnostics business in the US, Europe, and ROW. Prior to her time in diagnostics, she worked on the IND submission for VelcadeTM at Millennium Pharmaceuticals (acquired by Takeda). She started her laboratory career at the National Institutes of Health, holding laboratory positions in both the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Disease (NIAID). Hannah is a frequent speaker and writer on how to drive change in healthcare, and is on the editorial board for the Journal of Precision Medicine, where she also writes a regular column on the challenges of implementing change in medicine. Hannah serves on the Board of Directors for Bionano Genomics (BNGO) and a diagnostic company in stealth mode.
Hannah Mamuszka - Founder & CEO
Bio
LENA CHAIHORSKY - CO-FOUNDER & SVP PAYER INNOVATION
Lena is the co-founder and Senior Vice President of Payer Innovation at Alva10. With a background in biology and mathematics from Tufts, she is a skilled healthcare executive with a proven track record of developing and executing value based reimbursement strategies for diagnostics companies. Lena has extensive leadership experience in sales, national contracting, and all aspects of reimbursement within start-up and global companies, most recently AmniSure and QIAGEN. Lena also contributes to Alva10’s public speaking and writing efforts, leveraging her unique perspective on payer business and innovation models and their intersections with the diagnostics industry. Her work on commercial approaches to health economics data analysis led to her appointment as co-chair of the World Economic Forum’s workgroup dedicated to the economics of rare disease data federations in 2019. She is on the board of a bladder cancer diagnostics company, and leads the Novel Payment and Business Models Committee at Lab 2.0, a non-profit that fosters collaboration between diagnostics manufacturers and health system laboratories to center diagnostics as the driving force of population health.
Bio
As a small company, we hire based on team fit and passion. We are growing and looking to hire people with a passion to change and improve healthcare. Interested to learn more? Send us a message HERE.
Want to join our team?
As a small company, we hire based on team fit and passion. We are growing and looking to hire people with a passion to change and improve healthcare.
Interested to learn more?
Send us a message HERE.
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
Advisory Member - Title
Bio
Hannah has spent her 20+ year career in diagnostics - both in pharma and at diagnostics companies - in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data.
Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.
